Lung cancer remains the world's deadliest cancer, and a small but important group of patients carry a genetic change that standard treatments were never designed to target. That is where AstraZeneca (LSE:AZN) believes its antibody drug conjugate Enhertu can make a difference, and new Phase III data have strengthened that argument.

On 14 September 2026, the FTSE 100 drugmaker and its partner Daiichi Sankyo presented full results from the DESTINY-Lung04 trial. Enhertu delivered a median progression-free survival of 14.3 months as a first-line treatment for HER2-mutant advanced non-small cell lung cancer, well ahead of the current standard of care. The result could open a new, earlier-stage market for one of AstraZeneca's most important growth medicines.

From topline headline to a presidential symposium

The story began on 17 August 2026, when AstraZeneca announced that DESTINY-Lung04 had met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival. The company described it as the first Phase III trial of a HER2-directed therapy to show a progression-free survival benefit over the global standard of care in this first-line setting.

The detailed data followed in September at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer in Seoul, where the trial was selected for the Presidential Symposium. That billing is typically reserved for studies that experts regard as potentially practice-changing.

Susan Galbraith, AstraZeneca's executive vice president for oncology, said the results added to "growing evidence" supporting Enhertu for patients with HER2 alterations.

How the numbers stack up against chemotherapy and immunotherapy

DESTINY-Lung04 was a global, randomised, open-label study that enrolled 454 patients across Asia, Europe and North America. Patients received either Enhertu or the established first-line combination of platinum-pemetrexed chemotherapy plus pembrolizumab, an immunotherapy. The primary endpoint was progression-free survival assessed by blinded independent central review.

Enhertu achieved a median progression-free survival of 14.3 months, compared with 8.3 months for the chemotherapy and immunotherapy combination. The hazard ratio of 0.63 equates to a 37% reduction in the risk of disease progression or death, and the result was highly statistically significant. The objective response rate was 70.0% for Enhertu against 44.5% for the comparator arm.

Overall survival data are not yet mature, at around 47% of the required events, and were not formally tested. On safety, interstitial lung disease or pneumonitis, a known risk with Enhertu, occurred in 20.8% of patients treated with the drug. Most cases were low grade, but there were four fatal events, or 1.8% of patients.

Why an earlier lung cancer approval matters for AstraZeneca

HER2 mutations occur in roughly 2% to 4% of non-squamous non-small cell lung cancers, according to the company, and they disproportionately affect younger patients and people who have never smoked. That is a small slice of a very large disease: AstraZeneca's release cites around 2.6 million new lung cancer cases worldwide in 2024. Enhertu is already approved in more than 100 countries for previously treated HER2-mutant lung cancer, so moving into the first-line setting would allow patients to receive it earlier and potentially for longer.

Enhertu is one of the drugs at the centre of AstraZeneca's growth plans. It is already established in breast and gastric cancer, and each new indication adds to its Revenue potential. Oncology generated $14.1bn of revenue in the first half of 2026, up 15% at constant exchange rates and representing 46% of the group total, according to the company's half-year results on 27 July.

At the group level, first-half revenue rose 6% at constant exchange rates to $30.7bn, and core Earnings Per Share increased 11% to $5.21. AstraZeneca reconfirmed its full-year guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth, raised the Interim Dividend to $1.06 per share and reiterated its ambition of $80bn in total revenue by 2030. Positive late-stage readouts such as DESTINY-Lung04 are the kind of evidence that ambition relies on.

The caveats: safety, survival and shared economics

Not every aspect of the data was straightforward. The early overall survival figures did not favour Enhertu, although the analysis was immature, not formally tested and, according to the companies, may have been affected by imbalances in the treatments patients received after the trial drug. Regulators and doctors will want to see how survival develops as the data mature.

Lung toxicity is another consideration. Interstitial lung disease is a well-known risk with Enhertu and requires careful monitoring, and in a first-line setting clinicians will weigh a longer time without progression against that risk. The comparator regimen is also well established and familiar to oncologists, which could slow uptake even with approval.

For shareholders, it is worth remembering that Enhertu is jointly developed and commercialised with Daiichi Sankyo, which discovered and manufactures the drug, so the Economics are shared. More broadly, AstraZeneca faces pressures common to large pharmaceutical groups, including drug-pricing reform in the US, trade and Tariff uncertainty, and the constant need to replace revenue from older medicines as patents expire.

Regulatory filings and the next catalysts to watch

The most important next step is regulatory review. According to AstraZeneca's release, the first-line indication is pending regulatory review, and the timing of decisions from agencies such as the US Food and Drug Administration will determine when Enhertu can be used in this setting. Updated overall survival data will also be closely followed, because a clearer survival picture would strengthen the case with regulators, payers and prescribing doctors alike. Health technology assessment bodies in Europe, including those in the UK, will ultimately judge whether the benefit justifies the cost.

Beyond this trial, AstraZeneca's pipeline is extensive, with the company reporting 183 projects in development at the half-year stage. Its third-quarter results later this autumn will provide an update on Enhertu sales, oncology growth and whether full-year guidance remains intact. Further data readouts across its antibody drug conjugate portfolio are also likely to shape sentiment.

Conclusion

DESTINY-Lung04 gives AstraZeneca and Daiichi Sankyo a strong case for moving Enhertu into first-line treatment for HER2-mutant lung cancer, with a clear progression-free survival advantage and a much higher response rate than the current standard. Immature survival data, lung safety risks and shared economics temper the picture. Even so, the result adds another building block to AstraZeneca's oncology-led growth strategy, with regulatory decisions now the key milestone.